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Substantial evidence demonstrates both nicotine’s addiction liability and its cognition-enhancing effects.
However, the neurobiological mechanisms underlying nicotine’s impact on brain function and behavior
remain incompletely understood. Elucidation of these mechanisms is of high clinical importance and
may lead to improved therapeutics for smoking cessation as well as for a number of cognitive disorders
such as schizophrenia. Neuroimaging techniques such as positron emission tomography (PET), single
photon emission computed tomography (SPECT), and functional magnetic resonance imaging (fMRI),
which make it possible to study the actions of nicotine in the human brain in vivo, play an increasingly
important role in identifying these dual mechanisms of action. In this review, we summarize the current
state of knowledge and discuss outstanding questions and future directions in human neuroimaging
research on nicotine and tobacco. This research spans from receptor-level PET and SPECT studies
demonstrating nicotine occupancy at nicotinic acetylcholine receptors (nAChRs) and upregulation of
nAChRs induced by chronic smoking; through nicotine’s interactions with the mesocorticolimbic
dopamine system believed to mediate nicotine’s reinforcing effects leading to dependence; to functional
activity and connectivity fMRI studies documenting nicotine’s complex behavioral and cognitive effects
manifest by its actions on large-scale brain networks engaged both during task performance and at rest.
This article is part of the Special Issue Section entitled ‘Neuroimaging in Neuropharmacology’.
Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Nicotine’s addiction liability is demonstrated by the high prev-
alence of cigarette smoking and low quit success rates, despite
well-documented health risks (Bartal, 2001; Mokdad et al., 2004)
and societal costs (Leistikow, 2000; Leistikow et al., 2000;
Leistikow and Miller, 1998) of smoking. Approximately 20% of
Americans still smoke (Brown, 2009; CDC, 2009), and although
most smokers endorse a desire to quit (Fiore et al., 2000), very few
(<5%) will actually do so in a given year without treatment, and
only about 20e25% will achieve abstinence with 6 months or more
of effective treatment (Cahill et al., 2011; Holmes et al., 2004;
Hughes et al., 1999; Hurt et al., 1997; Jorenby et al., 1999; Killenat Los Angeles, Department
s, CA 90095, United States.
Jasinska), abrody@ucla.edu
CC BY-NC-ND license.et al., 1999, 2000). Therefore, there continues to be a vital need to
improve outcomes for cigarette smokers seeking treatment (Ray
et al., 2009).
Nicotine, an alkaloid found in tobacco leaves, has been used by
humans for its psychoactive properties for thousands of years. But it
is only in the last several decades that the cellular and physiological
mechanisms underlying nicotine’s complex effects on brain func-
tion and behavior, including nicotine’s abuse and dependence lia-
bility and its effects on cognitive function, have begun to be
revealed. Most of this fundamental knowledge has been obtained
from preclinical models and in vitro tissue preparations. More
recently, neuroimaging techniques such as positron emission to-
mography (PET), single photon emission computed tomography
(SPECT), and functional magnetic resonance imaging (fMRI) have
made it possible to study the actions of nicotine and cigarette
smoking on brain circuits and processes underlying addiction and
cognition in the human brain in vivo.
In this review, we summarize the current state of knowledge
and list some outstanding questions and possible future directions
in human neuroimaging research on nicotine and tobacco. This
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understanding of the effects of nicotine and tobacco smoking on
the human brain is a critical step toward the development of
more effective smoking cessation treatments, for which there is a
pressing need (CDC, 2009). At the same time, experimenter
administered nicotine can be used as a research tool to interrogate a
range of brain processes in both healthy and patient populations, as
well as to develop novel therapeutic drugs for such cognitive dis-
orders as schizophrenia, Alzheimer’s disease (AD), and attention-
deﬁcit hyperactivity disorder (ADHD).
2. Brain imaging of nicotinic acetylcholine receptors
Most psychoactive agents exert their effects by mimicking an
endogenous neurotransmitter and binding to its neuronal re-
ceptors. In this case, nicotine serves as a ligand at nicotinic acetyl-
choline receptors (nAChRs). nAChRs are ligand-gated ion channels
consisting of unique combinations from a family of at least seven-
teen (a1ea10, b1eb4, g, d, ε) similar, but distinct, subunits (Wu and
Lukas, 2011).Whilemany nAChR subtypes have been identiﬁed, the
heteromeric a4b2* receptor is one of the most common in the
mammalian brain (Wu et al., 2006), and will be the focus of this
section because the majority of brain imaging studies of smokers
have focused on this receptor. Receptors containing the a4 subunit
are reported to be central to the mediation of nicotine-induced
reward, tolerance, and sensitization (Perry et al., 2002), while
those containing the b2 subunit have been shown to be functionally
signiﬁcant in nicotine self-administration (Epping-Jordan et al.,
1999; Picciotto et al., 1998; Walters et al., 2006). Nicotinic acetyl-
choline receptors are located throughout the brain, with the
highest density seen in the thalamus, followed by the basal ganglia,
and frontal, cingulate, occipital, and insular cortices (Clarke et al.,
1984; Ding et al., 1996; Mamede et al., 2004).
For examining the acute and chronic effects of cigarette smoking,
PET and SPECT scanning have been performed in human smokers,
with the most commonly used radiotracers being 2-[18F]ﬂuoro-3-
(2(S)azetidinylmethoxy) pyridine (abbreviated as 2-FA) for PET
scanning (Koren et al., 1998) and 123-labeled 5-iodo-A-85380
(abbreviated as 5-IA) for SPECT scanning (Horti et al., 1999). These
radiotracers bind with high afﬁnity and relative speciﬁcity to a4b2*
nAChRs (Koren et al., 1998), and the safety and reliability of these
radiotracers have been veriﬁed (Bottlaender et al., 2003; Chefer
et al., 2003; Fujita et al., 2002; Kimes et al., 2008; Valette et al.,1999).
In examining the acute effects of smoking/nicotine administra-
tion, 2-FA PET and 5-IA SPECT studies have demonstrated the effect
of cigarette smoking on a4b2* nAChR occupancy. In one PET study,
smoking varying amounts of a regular cigarette (none,1 puff, 3 puffs,
1 full cigarette, or to satiety [2 ½e3 cigarettes]) resulted in 0, 33, 75,
88, and 95% receptor occupancy, respectively (Brody et al., 2006a)
(Fig. 1A). This study also demonstrated that smoking only 13% (1e2
puffs) of a cigarette and having a venous plasma nicotine
concentration of 0.87 ng/mL (roughly 1/25th of the level achieved
in typical daily smokers) resulted in 50% occupancy of a4b2*
nAChRs for 3.1 h after smoking. Therefore, cigarette smoking in
amounts used by typical daily smokers leads to nearly complete
occupancy of a4b2* nAChRs, such that tobacco-dependent smokers
maintain a4b2* nAChR saturation throughout the day. In a similar
study using 5-IA SPECT (Esterlis et al., 2010), smoking to satiety
(mean e 2.4 cigarettes) also resulted in a prolonged period of occu-
pancy of themajority of b2*-containing nAChRs (meane 67% [range,
55e80%]). The actual percent occupancy from smoking to satiety for
the second study was lower than the ﬁrst, and these slightly
discrepant results may have been due to differences in abstinence
period before scanning, number of cigarettes smoked during scan-
ning, imaging methodology/timing issues, brain regions studied,and/or statistical calculation methods for determining percent
occupancy.
In addition to studies examining regular cigarette smoking,
other acute cigarette smoke exposures (namely denicotinized and
low nicotine cigarettes, and secondhand smoke) have recently been
examined for their effects on a4b2* nAChR occupancy. In one study
(Brody et al., 2009a) (Fig. 1B), denicotinized cigarettes containing
only trace amounts of nicotine (0.05 mg) and low nicotine ciga-
rettes (0.6 mg nicotine) were smoked during 2-FA PET scanning to
determine if components of smoking other than nicotine (e.g.,
other constituents of tobacco smoke or the touch, feel, smell, and
taste of a cigarette) result in a4b2* nAChR occupancy. This study
demonstrated that smoking a denicotinized and a low-nicotine
cigarette resulted in 26% and 79% a4b2* nAChR occupancies,
respectively. Given the consistency of ﬁndings between this study
and the one cited above with standard cigarettes (Brody et al.,
2006a), the denicotinized/low nicotine cigarette study demon-
strates that nicotine inhalation during smoking appears to be solely
responsible for a4b2* nAChR occupancy, with other factors (if
present at all) having either short-lived or very minor effects. And
in a second study, secondhand smoke exposure (Brody et al., 2011)
was also found to occupy a substantial percentage of a4b2* nAChRs
(Fig. 1C). In this study, smokers and nonsmokers underwent two
PET scanning sessions, during which they sat in the passenger’s seat
of a car for 1 h and either were or were not exposed to secondhand
smoke from a smoker seated in the driver’s seat. In this study, the
secondhand smoke exposure resulted in 19% occupancy of a4b2*
nAChRs, with no signiﬁcant differences between smokers and
nonsmokers, again demonstrating substantial receptor occupancy
from cigarette smoke exposure.
Medications for treating tobacco dependence have also been
examined for their acute effects on a4b2* nAChR occupancy. In one
SPECT scanning study (Esterlis et al., 2011), use of a nicotine inhaler
produced an average 55.9% occupancy of b2*-nAChRs 2e5 h post-
challenge, which was less than the occupancy produced by smok-
ing a standard cigarette (67.6%). Use of the nicotine inhaler was
associated with diminished cigarette withdrawal, but not craving,
possibly indicating that higher nAChR occupancy than is achieved
with the nicotine inhaler is needed to reduce craving (or perhaps
other conditional stimuli such as the taste and feel of the smoke in
the throat, etc, may be required to diminish craving). In a similar
study comparing varenicline (Chantix) to placebo administration
during PET scanning sessions (Lotﬁpour et al., 2012), low dose
varenicline administration (0.5 mg) was associated with complete
saturation of available a4b2* nAChRs. Smoking to satiety, but not
low-dose varenicline, signiﬁcantly reduced withdrawal symptoms,
indicating that factors other than varenicline binding to a4b2*
nAChRs lead to reduced withdrawal.
As for chronic effects of smoking/nicotine administration,
several lines of research demonstrate that smoking leads to up-
regulation of nAChRs in the human brain, including the common
a4b2* nAChR (Gentry and Lukas, 2002). Human postmortem tissue
studies show that chronic smokers have increased numbers of
a4b2* nAChRs compared to non-smokers (Benwell et al., 1988;
Breese et al., 1997), and that former smokers (>1 year abstinent)
have nAChR densities similar to non-smokers (Breese et al., 1997).
Many laboratory animal studies also demonstrate up-regulation of
nAChRs in response to chronic nicotine administration (Marks
et al., 2011; Pauly et al., 1989, 1996; Shoaib et al., 1997; Yates
et al., 1995; Zhang et al., 2002). Taken together, these studies
indicate that nAChRs up-regulate with smoking or nicotine
administration, but that this up-regulation is reversible with an
extended period of abstinence from smoking.
PET and SPECT brain imaging studies of human smokers, using
2-FA and 5-IA, have demonstrated up-regulation of available a4b2*
Fig. 1. Positron emission tomography (PET) studies using 2-[18F]ﬂuoro-3-(2(S)-azetidinylmethoxy) pyridine (abbreviated as 2-FA) to image a4b2* nicotinic acetylcholine receptor
(nAChR) occupancy from cigarette smoke exposure in humans in vivo. (A) Nicotine intake obtained from cigarette smoking in amounts used by typical daily smokers leads to nearly
complete occupancy of a4b2* nAChRs, indicating that tobacco-dependent smokers maintain a4b2* nAChR saturation throughout the day. Horizontal slices at the level of the
thalamus are shown. Modiﬁed from Brody et al. (2006a). (B) Relatively small amounts of nicotine in a denicotinized cigarette (Q-3, 0.05 mg nicotine) and a low-nicotine cigarette (Q-
1, 0.6 mg nicotine) result in 26% and 79% a4b2* nAChR occupancies, respectively, across thalamus (top panel), brainstem (bottom panel), and cerebellum (not shown). Modiﬁed from
Brody et al. (2009a). (C) Similarly, nicotine from moderate second-hand smoke exposure results in 19% occupancy of a4b2* nAChRs in both smokers (shown) and non-smokers.
Modiﬁed from Brody et al. (2011).
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regions other than the thalamus (Brody et al., 2012; Cosgrove et al.,
2009, 2012; Mamede et al., 2007; Mukhin et al., 2008; Staley et al.,
2006; Wullner et al., 2008). In follow-up scanning of smokers in
two of these studies, nAChR up-regulation was found to normalize
to levels of non-smokers when participants were given contin-
gency management to maintain abstinence for roughly three
(Mamede et al., 2007) to twelve (Cosgrove et al., 2009) weeks.
Furthermore, these studies indicate that a4b2* nAChR up-
regulation in smokers is more pronounced in men (Cosgrove
et al., 2012), menthol cigarette smokers (Brody et al., 2012), and
smokers who have higher levels of urge to smoke to relieve with-
drawal symptoms (Staley et al., 2006).
3. Ventral striatal dopamine signaling and tobacco
dependence
Both pre-clinical and clinical studies have demonstrated the
reinforcing effects of nicotine and its potential for abuse and
dependence, although other aspects of cigarette smoking may also
contribute to these effects, including reinforcing effects of non-nicotinic components in tobacco smoke (for review, see (Rose,
2006)) and cognition-enhancing effects of nicotine (discussed in
the section below). As with other drugs of abuse, the development
of nicotine dependence in cigarette smokers occurs in several
stages, starting with initial experimentation and recreational use,
most often in adolescence, followed by a transition to chronic use,
and ultimately escalating to abuse and dependence in susceptible
individuals.
Similar to other drug use, cigarette smoking facilitates dopa-
mine (DA) release in the ventral striatum (VST), thereby resulting in
a “hijacking” of the brain’s reward circuitry (Baler and Volkow,
2011; Volkow et al., 2012; reviewed in De Biasi and Dani, 2011).
In addition, the phenomenon of maladaptive behaviors resulting
from DA signaling in the VST has also been proposed to contribute
to non-substance related behavioral addictions, including obesity
(Volkow et al., 2011) and pathological gambling (Leeman and
Potenza, 2012). DA release in the VST/nucleus accumbens (NAc),
among other regions, in response to nicotine is thought to be due to
the activation of nAChRs on upstream DA neurons in the ventral
tegmental area (VTA), the area of the midbrain containing cell
bodies of DA neurons that project to the VST (Nisell et al., 1994). A
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addictive behaviors has clearly demonstrated the primacy of VST
DA release in the development of addictive behaviors, including
tobacco dependence.
Evidence for facilitation of DA release in the VST/nucleus
accumbens (NAc) as underlying the reinforcing properties of
nicotine has been most extensively demonstrated in rodent labo-
ratory models (De Biasi and Dani, 2011). Data from non-human
primates have also contributed to the understanding of VST DA
release in tobacco dependence, showing that intravenous (IV)
nicotine administration causes DA release (Dewey et al., 1999;
Domino and Tsukada, 2009; Marenco et al., 2004; Tsukada et al.,
2002), increased DA synthesis (Tsukada et al., 2005, 2002), and
increased total catecholamine synthesis (Domino et al., 2009).
Laboratory results from non-human primates and rodent models
have thus provided convincing evidence that the mammalian
dopaminergic VST reward pathway has both the appropriate
neurochemical circuitry and experimental response to pharmaco-
logical manipulation to implicate this circuit as being important for
tobacco dependence.
Molecular brain imaging studies of the human (and non-human
primate) VST DA system also strongly support the importance of
this pathway in the pathophysiology of human tobacco depen-
dence. Many studies have demonstrated that inhaled tobacco
smoke can displace 11C-raclopride from VST DA D2/3 receptors in
human smokers (Barrett et al., 2004; Brody et al., 2004b, 2006b,
2010, in press; Domino et al., 2012a,b; Scott et al., 2007), showing
that smoking behavior produces in vivo VST DA release. Although
insufﬂated nicotine did not produce a group difference in VST DA
release, the degree of change among smokers was correlated with
positive feeling states; this lack of effect of nicotine nasal spray was
attributed to the fact that “cigarette smoking is more likely to have
activated reward circuitry than intranasal nicotine” (Montgomery
et al., 2007). Smokers using nicotine gum were also found to have
decreased VST 11C-raclopride binding compared to matched pla-
cebo, with no effect of gum on a non-smoking control group
(Takahashi et al., 2008).
Smoking-induced VST DA release has also been linked to asso-
ciated behavioral and neurochemical changes in human smokers,
including increased hedonic response (Barrett et al., 2004),
increased striatal opioid receptor activation (Scott et al., 2007), and
improved self-reported mood (Brody et al., 2009b), demonstrating
that smoking-related VST DA release correlates with other markers
of smoking behavior in humans. The relationship between mood
disorders and smokingwas further explored in a study that showed
that smokers with vs. without a history of major depression had a
greater mean decrease in 11C-raclopride binding potential before to
after smoking a cigarette during PET scanning (Brody et al., 2009c).
Additional evidence of VST DA signaling abnormalities in smokers
was demonstrated in a study of response to challengewith 30mg of
d-amphetamine, where smokers showed blunted VST DA release
compared to non-smokers (Busto et al., 2009). The genetic control
of smoking-induced VST DA release has been demonstrated both
for DA transporter alleles (Brody et al., 2006b) and mu opioid re-
ceptor alleles (Domino et al., 2012a). Therefore, multiple lines of
evidence from studies of molecular imaging of smoking behavior,
combined with concomitant pharmacological, psychological, and
genetic evidence conclusively demonstrate that human smoking
behavior is associated with VST DA release.
Given the established association between substance use dis-
orders, related behavior addictions (such as obesity) and decreased
VST D2/3R availability, baseline striatal DA tone has been increas-
ingly recognized as a risk factor for addiction (Volkow et al., 2012).
Therefore, many studies in human smokers have also attempted to
assess whether the same holds true for human smokers; however,the evidence is mixed. Several studies utilizing SPECT with DA re-
ceptor ligands 123I-beta-CIT (Staley et al., 2001) and 123I eBZM
(Yang et al., 2006, 2008) found that smokers and non-smokers did
not differ in terms of baseline VST DA receptor binding, despite one
of these studies showing (in accordance with earlier ﬁndings
(Salokangas et al., 2000)) that smokers had decreased VST DA
transporter density (Yang et al., 2008). A limitation of these studies,
admittedly, was small sample sizes, which may have limited their
power to detect subtle differences in baseline VST DA receptor
availability (Yang et al., 2008). Conversely, several studies with
larger sample sizes using the PET radiotracer 18F-fallypride did
report baseline lower striatal DA receptor availability in smokers
compared to non-smoking controls; one study found that smokers
had less putamen DA D2/3R availability than non-smokers (Fehr
et al., 2008), and a second found decreased striatal DA availability
in smokers vs. non-smokers only in male, but not female, subjects
(Brown et al., 2012). Additional studies with larger sample sizes are
needed to conclusively determine whether human smokers have
lower baseline striatal D2/3R availability.
Investigation into the relative role of D1 vs. D2/3 receptors in
human tobacco-related VST DA signaling has also followed from
work in animal models. In a group of smokers seeking treatment,
increased left VSTmetabolismwas seenwith craving, and therewas
an inverse correlation of VST D1 receptor availability and both VST
metabolism and craving (Yasuno et al., 2007). Supporting the re-
sults of earlier work (Dagher et al., 2001), smokers also showed an
overall decrease in VST D1R availability compared to controls;
however, there was no recovery in VST D1R availability in smokers,
even after 6 months of abstinence (Yasuno et al., 2007).
To summarize these results of DA signaling in tobacco depen-
dence, ample evidence from both animal models and human
smokers supports the hypothesis that both smoking behavior and
nicotine administration result in activation of the VST reward
pathway, via increased DA release and metabolism in the VST. This
phenomenon may provide a common link between tobacco
dependence and other human substance and non-substance
behavioral addictions (Baler and Volkow, 2011; Volkow et al.,
2011, 2012). Indeed, recent studies suggest that both acute (Rose
et al., 2012b) and chronic (Rose et al., 2012a) exposure to nicotine
is associated with altered reward-related striatal activity.
4. Acute and chronic nicotine actions on brain function and
structure
A number of human neuroimaging studies have examined the
effects of acute nicotine administrationor cigarette smokingonbrain
activity in smokers in the absence of any explicit cognitive task. In an
early fMRI study using cumulative intravenous nicotine adminis-
tration (0.75, 1.50, and 2.25mg/70 kg of weight) in non-deprived
smokers, Stein and colleagues (Stein et al., 1998) demonstrated that
nicotine increased the Blood oxygenation level dependent (BOLD)
fMRI signal in a number of cortical and subcortical regions, including
the insula, the cingulate cortex, the dorsolateral, orbital, and medial
prefrontal cortices, and portions of the temporal and occipital
cortices, as well as the nucleus accumbens (NAc), amygdala, hypo-
thalamus, and several nuclei of the thalamus. Early PET studies
(Domino et al., 2000, 2004; Zubieta et al., 2001, 2005) using either
nasal nicotine spray (vs. pepper solution spray) or nicotine cigarettes
(vs. de-nicotinized cigarettes) in smokers after overnight abstinence
showed that nicotine increased regional cerebral blood ﬂow (rCBF)
in the thalamus, occipital cortex, and cerebellum, but variably
decreased rCBF in the amygdala, NAc, hippocampus, temporal cortex,
and cingulate cortex.
Several neuroimaging studies have recently examined the
impact of nicotine and tobacco on large-scale brain networks. These
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in temporal ﬂuctuations in BOLD signal across brain regions
(Beckmann et al., 2005; Fox et al., 2005; Greicius et al., 2003). Such
identiﬁed networks are also engaged during a variety of cognitive
tasks, and are believed to reﬂect the underlying structural and
functional architecture of the human brain (Greicius et al., 2009;
Smith et al., 2009; van den Heuvel et al., 2009). Therefore, an
important goal for neuroimaging pharmacological research is to
evaluate the impact of nicotine and tobacco on the coherence and
dynamic interactions of these networks (for a recent review, see
Sutherland et al., 2012).
Hong and colleagues examined the effects of acute nicotine
patch administration on the resting-state functional connectivity
(rsFC) in brain circuits centered on the cingulate cortex in smokers.
Acute nicotine enhanced connectivity between several sub-
dividions of the cingulate cortex and a number of frontal and pa-
rietal cortex regions. In contrast, the severity of nicotine
dependence was speciﬁcally and negatively associated with a dor-
sal anterior cingulate (dACC)-VST circuit, suggesting a dissociation
of acute (state-like) and chronic (addiction trait) nicotine effects on
intrinsic brain function (Hong et al., 2009). Negative correlations
between smoking severity and rsFC strength between the dACC,
striatum, and insula were also found in smokers with schizo-
phrenia, with an additive effect of schizophrenia diagnosis and
smoking on the reduction in the dACCeinsula connectivity (Moran
et al., 2012). Furthermore, similar results were reported in a
smoking-cue reactivity paradigm, with smokers who subsequently
slipped during their quit attempt displaying reduced dACCeinsula
connectivity strength when viewing smoking cues compared to
smokers who remained abstinent (Janes et al., 2010). Thus, the
altered functional connectivity of the dACC and related regions
observed at rest may be associated with altered reactivity to
smoking cues, among other task-related consequences.
Cole et al. (2010) investigated the effects of nicotine replace-
ment on the interactions between the default mode network
(DMN) and executive control network (ECN) in abstinent smokers
(Fig. 2A). These two brain networks show anti-correlated patterns
of activity: the ECN is thought to be engaged during attention-
demanding cognitive tasks, whereas the DMN is activated during
rest and often deactivated during cognitive task performance
(Raichle et al., 2001), with a larger degree of DMN deactivation
associated with better task performance (Kelly et al., 2008;
Weissman et al., 2006). Using a double-blind, placebo-controlled
design, Cole et al. (2010) found that the therapeutic effect of nico-
tine replacement on cognitive withdrawal symptoms was associ-
ated with enhanced inverse coupling between the ECN and DMN,
whereas non-responders showed no effect of nicotine replacement
on ECNeDMN coupling. Similarly, Tanabe et al. (2011) investigated
the effects of a 7 mg nicotine patch on resting-state activity in the
DMN and visual attention network in non-smoking subjects
(Fig. 2B). This study showed that acute nicotine suppressed activity
within the DMN and increased activity in extra-striate regions
within the visual attention network, even in the absence of explicit
task and effortful processing, suggesting that nicotine’s cognition-
enhancing effects may involve shifting network activity from
internally-directed to externally-directed processes. A reanalysis of
these data with network topology techniques (Wylie et al., 2012)
also revealed that acute nicotine increased local efﬁciency of the
network, as well as regional efﬁciency for limbic and paralimbic
brain regions, in healthy non-smokers. Consistently, Hahn et al.
(2007) also observed nicotine-induced DMN deactivation during
performance of a selective attention task. Overall, these recent
neuroimaging studies of nicotine’s effects on network dynamics ﬁt
well with the view that the endogenous cholinergic system mod-
ulates both local and global aspects of information processing in thebrain, and are consistent with neuroanatomical evidence of global
cholinergic projections from the nucleus basalis and widely
distributed acetylcholine-responsive interneurons (Mesulam and
Geula, 1988; Xiang et al., 1998).
While investigations of the impact of chronic experimental
nicotine administration on the human brain still present a chal-
lenge, several neuroimaging studies examined the effects of
chronic cigarette smoking on structural brain measures. Using
high-resolution structural MRI, Brody et al. (2004a) demonstrated
smaller gray matter volume and lower gray matter densities in
bilateral prefrontal cortex (PFC), along with smaller volume in the
left dACC, in smokers compared to matched non-smoking controls.
Furthermore, the gray matter densities in the PFC negatively
correlated with the magnitude of lifetime smoking exposure as
indexed by pack-years smoked. Similarly, Gallinat et al. (2006)
showed that, compared to never-smokers, smokers presented
with smaller gray matter volume and lower gray matter density in
the frontal lobe (ACC, PFC, and orbitofrontal cortex, or OFC), oc-
cipital lobe, and temporal lobe (including parahippocampal gyrus),
as well as volume or density deﬁcits in the thalamus and cere-
bellum. Again, the gray matter volume in frontal, temporal, and
cerebellar cortices was inversely correlated with lifetime smoking
exposure in smokers (Gallinat et al., 2006). Cortical thinning of the
medial OFC in smokers compared to never-smokers was also
replicated (Kühn et al., 2010), including a negative association be-
tween the cortical thickness of the OFC and both daily and lifetime
exposure to tobacco smoke.
Using diffusion tensor imaging (DTI) and fractional anisotropy
(FA) as a measure of white matter integrity, Zhang et al. (2011)
demonstrated that the most dependent smokers had lower pre-
frontal FA, which was negatively correlated with addiction severity
as measured by FTND. In addition, smokers showed higher gray
matter density in left insular cortex (Zhang et al., 2011), consistent
with previous evidence of the role of the insula in supporting to-
bacco dependence (Naqvi and Bechara, 2009; Naqvi et al., 2007).
Finally, chronic smoking and a diagnosis of schizophrenia have
been shown to independently and additively reduce the FA of the
white-matter ﬁbers connecting the PFC with the striatum and
thalamus (Zhang et al., 2010), suggesting that these two highly co-
morbid conditions have both common and distinct effects on brain
structure, consistent with their additive, detrimental effects on
functional-connectivity networks (Moran et al., 2012).
5. Acute nicotine modulation of cognitive brain function
In addition to its well-documented addiction liability, nicotine is
also known to enhance aspects of cognitive function, including
attention and memory (for a recent meta-analysis, see Heishman
et al., 2010). This nicotine-induced enhancement of cognitive
function has been observed both in nicotine-deprived smokers (in
whom it may be due, at least in part, to relief of withdrawal), in
non-deprived smokers, and in non-smokers (in whom it may
reﬂect a true enhancement of cognitive function and/or an atten-
uation of pre-existing cognitive deﬁcits) (Heishman et al., 2010).
Indeed, nicotine and other nAChR ligands are being investigated as
potential therapeutics for the treatment of cognitive deﬁcits in
schizophrenia, attention-deﬁcit hyperactivity disorder, and Alz-
heimer’s disease (D’Souza andMarkou, 2012; Levin et al., 2006). On
the other hand, chronic cigarette smoking has been associated with
decreased cognitive performance in middle age (Kalmijn et al.,
2002; Richards et al., 2003) and increased risk of cognitive
decline and dementia later in life (for a meta-analysis, see Anstey
et al., 2007). Human neuroimaging research has begun to eluci-
date the brain circuits and processes mediating the effects of acute
nicotine and chronic cigarette smoking on cognitive function and
Fig. 2. Blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) and regional cerebral blood ﬂow (rCBF) PET studies of nicotine effects on
functional brain networks during (A, B) task-free resting state and (C, D) cognitive task performance. (A) Activation in the executive control network (ECN), encompassing ACC,
DLPFC, and PPC, is anti-correlated with the default mode network (DMN), containing MPFC and PCC, during task-free resting state (top panel). Relative to placebo, nicotine
enhanced the ECNeDMN anti-correlation in abstinent smokers who demonstrated a reduction in withdrawal symptoms following nicotine replacement (top time-course), but not
in those who did not show such response (bottom time-course). Modiﬁed from Cole et al. (2010). (B) Nicotine decreased DMN activity (including MPFC and PCC) relative to pre-
nicotine baseline during resting state in non-smokers. Modiﬁed from Tanabe et al. (2011). (C) Nicotine enhanced deactivation in the DMN (including MPFC and PCC) during a spatial
attention task in minimally deprived smokers relative to placebo. Modiﬁed from Hahn et al. (2007). (D) Using rCBF PET, nicotine enhanced DLPFC response (within the ECN) during
2-back working memory task in ex-smokers but reduced it in ex-smokers, relative to placebo. Modiﬁed from Ernst et al. (2001). Abbreviations: ACC, anterior cingulate cortex;
DLPFC, dorsolateral prefrontal cortex; DMN, default mode network; ECN, executive control network; MPFC, medial prefrontal cortex; PCC, posterior cingulate cortex; PPC, posterior
parietal cortex.
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2011; Newhouse et al., 2011). A brief and selective review of
acute nicotine and cigarette smoking on cognitive processes is
presented below.
5.1. Sustained attention
Lawrence et al. (2002) used fMRI to assess acute effects of a
21 mg transdermal nicotine patch on the neural correlates of sus-
tained attention in mildly abstinent smokers. Using the rapid visualinformation-processing (RVIP) task, behavioral performance was
associated with increased activity in the middle and inferior frontal
cortices, anterior insula, parietal and occipital cortex, thalamus,
caudate, and cerebellum, as well as with signal decreases in the
medial frontal cortex, anterior and posterior cingulate, mid-insula,
parahippocampus, and amygdala. In the placebo condition,
smokers showed less task-induced activation in parietal cortex and
caudate compared to non-smokers, whereas smokers on nicotine
patch showed increased task-related activation in parietal cortex,
caudate, and thalamus, as well as a general increase in activation in
A.J. Jasinska et al. / Neuropharmacology 84 (2014) 111e122 117the occipital cortex. Furthermore, smokers showed a trend toward
a worse performance than non-smokers, but an improvement in
performance in the nicotine condition compared to the placebo
condition. Using the same task in participants with schizophrenia
(Hong et al., 2011), nicotine produced generalized increases in
activation in the frontal, insular, cingulate, parietal, and occipital
cortices, and in the basal ganglia, midbrain, and cerebellum, and
enhanced task performance, relative to the placebo conditions,
with similar effects in patients and controls (i.e., no
drug  diagnosis interactions). Patients showed reduced task-
related activations and impaired task performance compared to
healthy controls in the placebo condition as well as on nicotine
patch, suggesting that acute nicotine cannotdor the dose of nico-
tine used was not sufﬁcient todnormalize the neural and behav-
ioral deﬁcits in the patient group (Hong et al., 2011).
Warbrick et al. (2012) used simultaneous fMRI and EEG to
examine the effects of 1 mg nasal nicotine spray on the neural
response to a visual oddball task in smokers. Compared to the
placebo condition, nicotine decreased reaction times, which was
associatedwith reduced BOLD response in the superior parietal and
lateral occipital cortices and precuneus, Interestingly, they also
analyzed their data informed by single-trial P3 component ampli-
tude and found increased BOLD response in the precentral and
postcentral gyri and ACC, highlighting the fact that different tem-
poral resolutions of measurement (here: high temporal resolution
of EEG coupled with more sluggish fMRI BOLD time-course) may
provide complementary information about the underlying brain
processes.
5.2. Selective attention
A series of fMRI studies (Giessing et al., 2006; Thiel and Fink,
2008; Thiel et al., 2005; Vossel et al., 2008) examined the effects
of 2 mg nicotine gum on the neural correlates of selective visuo-
spatial attention as assessed with a cued target detection task in
non-smoking subjects. In these studies, re-orienting of attention
was isolated by contrasting invalid-cue trials with valid-cue trials,
and was associated with activation in the parietal, temporal, and
middle frontal cortices. Acute nicotine reduced the BOLD response
to invalidly cued trials in the parietal cortex as well as in the
temporal, middle frontal, and cingulate cortices, which was in some
cases accompanied by behavioral enhancement (i.e., speeded re-
action times). Two studies by Stein and colleagues (Hahn et al.,
2007, 2009) also examined the effects nicotine patch on the neu-
ral correlates of cued selective attention in mildly deprived
smokers (Fig. 2C). These studies showed that nicotine reduced the
activation (or induced deactivation) to all cued trials in the parietal
cortex (angular gyrus), middle frontal cortex, and anterior and
posterior cingulate cortices. These regions overlap with the DMN
(Raichle et al., 2001). Consistent with the known predictive rela-
tionship between task performance and DMN deactivation (Kelly
et al., 2008; Weissman et al., 2006), nicotine-induced deactiva-
tion in angular gyrus and posterior cingulate was positively corre-
lated with performance improvements in smokers, controlling for
nicotine plasma levels (Hahn et al., 2007). Furthermore, Rose et al.
(2010) showed that the modulatory effects of acute nicotine on
task-related brain response in smokers were not limited to atten-
tional processes but extended to intentional and motor preparation
processes. Compared to the placebo condition, nicotine increased
the response to the intentional prime (signaling whether left or
right hand response would be required) in the left inferior parietal
lobule and supramarginal gyrus, as well as in the left postcentral
gyrus; in contrast, nicotine decreased the response in the left
postcentral gyrus to attentional primes (signaling whether the
target will appear on the left or right side of the screen).5.3. Working memory
In an early study of nicotine effects on working memory (WM),
Ernst et al. (2001) used PET to measure changes in rCBF and
examined the impact of 4 mg nicotine gum on brain activity during
an n-back task in heavy smokers after overnight abstinence and in
light ex-smokers (Fig. 2D). Consistent with numerous WM studies
(Wager and Smith, 2003), in the placebo condition, the n-back task
increased rCBF in the ACC, dorsolateral prefrontal (DLPFC), and
inferior parietal cortices, with better task performance associated
with stronger prefrontal activation in both smokers and ex-
smokers (Ernst et al., 2001). In both smokers and ex-smokers,
nicotine reduced rCBF in cingulate cortex relative to the placebo
condition. In addition, nicotine enhanced activation in the pre-
frontal and parietal regions in ex-smokers, whereas it decreased
prefrontal and parietal activation in current smokers.
Taking a different approach, Xu et al. (2005) used fMRI to
compare brain activity during the n-back WM task in the same
group of nicotine-dependent smokers during satiety (1.5 h
abstinence) and following abstinence (14 h abstinence), in an
attempt to explain the abstinence-related deﬁcits in WM in
smokers. This study showed an interaction of test condition
(satiety, abstinence) and task load (1-back, 2-back, and 3-back) on
DLPFC activity: whereas in a satiated state, the DLPFC activity was
low during the easy 1-back condition and increased in the more
difﬁcult 2- and 3-back condition, in the abstinent state, the DLPFC
was relatively high in the 1-back condition but failed to increase
with increased working memory load. A follow-up study (Xu et al.,
2006) compared the effects of smoking a cigarette following ad
libitum smoking or overnight abstinence on DLPFC activity, and
reported a 3-way interaction between acute smoking (pre- or post-
cigarette), test session (smoking or abstinence), and n-back task
load. Speciﬁcally, post-cigarette DLPFC activity was higher than
pre-cigarette at low task load and lower at high task load after ad
libitum smoking; in contrast, post-cigarette DLPFC activity was
lower than pre-cigarette at low task load and higher at high task
load following overnight abstinence. This pattern of activity sug-
gests that the impact of acute smoking on WM processes in
smokers depends on their recent smoking history and cognitive
load: acute smoking after abstinence improves WM processes
(presumably by alleviating withdrawal), whereas the effects of
acute smoking in the satiated state varies with the WM difﬁculty
(Xu et al., 2006).
The above interactions may explain the absence of acute (but
not chronic) nicotine effects in a study by Sutherland et al. (2011),
which examined the neural correlates of a WM task with an
additional attentional-switch requirement in minimally deprived
smokers. In another study, Kumari et al. (2003) used fMRI to
examine the impact of acute nicotine administration on neural
correlates of WM in a parametric n-back task in healthy non-
smoking males. Compared to placebo, nicotine improved task
performance as well as increased the BOLD response in the ACC,
superior frontal, and superior parietal cortices that were activated
by the n-back task. With respect to clinical groups, Jacobsen et al.
(2004) examined the impact of nicotine patch (vs. placebo patch)
on brain activity during an auditory WM task in schizophrenia
subjects and healthy smokers. During the most difﬁcult dichotic 2-
back task condition, nicotine enhanced activation in the ACC and
thalamus, as well as thalamo-cortical functional connectivity, to a
greater degree in schizophrenic patients than in control subjects;
nicotine also improved task performance of patients, whereas it
decreased task performance in control subjects in this condition.
In sum, neuroimaging studies of acute nicotine modulation of
cognitive function are in agreement with behavioral studies and
paint an equally complex picture. Nicotine-induced enhancement
Fig. 3. A simpliﬁed diagram of nicotine’s dual action in the brain. Nicotine’s reinforcing
and cognition-enhancing properties may be linked at least in part by nicotine-induced
enhancement of DA signaling in the mesolimbic and mesocortical DA pathways,
respectively. ACC, anterior cingulate cortex; DARs, dopamine receptors; NAc, nucleus
accumbens; nAChRs, nicotinic acetylcholine receptors; PFC, prefrontal cortex; VST,
ventral striatum; VTA, ventral tegmental area.
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tivity in subcortical regions such as basal ganglia and thalamus, as
well as with both increases and decreases in activity in frontal and
parietal cortices. In addition, the impact of acute nicotine on task-
related brain responses may be further modulated by the dose
and route of administration, length of abstinence in smokers, and
pre-existing cognitive deﬁcits such as those associated with
schizophrenia or ADHD diagnosis, as well as by the type and dif-
ﬁculty of the task itself. Thus, overall, nicotine seems to enhance
executive function not via a single neuroanatomical site or mech-
anism, but via its modulation of multiple brain networks and
transmitter systems, requiring a more speciﬁc characterization of
nicotine effects on diverse task-induced tonic and phasic neuronal
states. In particular, and consistent with nicotine-induced (or
enhanced) down-regulation of the ‘default mode’ function
observed across a range of different task paradigms (for review, see
Bentley et al., 2011), nicotine may modulate the ‘toggle’ between
the DMN and ECNda key role attributed to a proposed dACCe
insula network (Menon and Uddin, 2010; Seeley et al., 2007).
6. Linking nicotine’s roles in addiction and cognition
As reviewed in the sections above, nicotine has a dual action in
the brain: it promotes addiction (Tuesta et al., 2011) and it modu-
lates cognition (Bentley et al., 2011). Although typically investi-
gated separately, both clinical evidence and theoretical accounts
suggest that nicotine’s addictive and cognitive properties are
closely linked and interact in important ways. Individuals may self-
medicate with nicotine to enhance cognitive and attentional pro-
cesses (Evans and Drobes, 2009), which may partially account for
the high prevalence of cigarette smoking among individuals with
cognitive disorders such as schizophrenia, ADHD, or AD. Similarly,
nicotine withdrawal symptoms include both cognitive deﬁcits and
deﬁcits in reward processing and motivation. Thus, nicotine’s
reinforcing and cognition-enhancing effects are likely to involve at
least partially overlapping brain processes, networks, and trans-
mitter systems.
In particular, nicotine may exert its reinforcing and cognition-
enhancing effects at least in part by enhancing DA signaling in
mesolimbic and mesocortical DA pathways, respectively (Fig. 3). In
addition to its well-established role in addiction, DA is also a critical
modulator of a range of cognitive processes (for a recent review, see
Cools and D’Esposito, 2011). Although some overlap exists, DA’s role
in addiction has been associated primarily with mesolimbic DA
pathways connecting the VTA with VST and amygdala, whereas
DA’s effects on cognition may be mediated by the mesocortical DA
pathways connecting the VTA with the cortical regions, including
the PFC. nAChRs are present on VTA DA projection neurons (Clarke
and Pert, 1985; Deutch et al., 1987) and are known to enhance the
activity of these neurons and DA release (Calabresi et al., 1989;
Imperato et al., 1986). Therefore, it is likely that by binding to
nAChRs in the VTA, nicotine enhances DA signaling in both meso-
limbic and mesocortical DA pathways, and therefore also enhance
the processes mediated by their target brain regions and networks,
leading to nicotine addiction and nicotine-induced cognitive
enhancement, respectively.
Further indirect evidence linking nicotine and DA stems from
the observation that nicotine and DA agonists present similar
inverted-U doseeeffect curves with respect to both intensity of
drug self-administration and cognitive task performance. Thus, in
self-administration studies of nicotine and stimulants such as
cocaine, the ascending limb of the doseeresponse curve is thought
to represent the increasingly rewarding or reinforcing properties of
increasing dosage of the drug, whereas the descending limb of the
doseeresponse curve reﬂects the aversive properties of high drugdoses as well as receptor satiation (for review, see Lynch and
Carroll, 2001). In studies of nicotine’s effects on cognition,
absence of nicotine in heavy smokers produces cognitive deﬁcits
characteristic of withdrawal (similar deﬁcits are seen with nAChR
antagonists in non-smokers), moderate doses of nicotine typically
produce cognitive enhancement (and/or alleviation of withdrawal-
related cognitive deﬁcits in smokers), whereas very high doses of
nicotine typically impair cognitive performance (for review, see
Bentley et al., 2011). And analogously, in studies of DA’s role in
cognition, DA depletion impairs cognitive processing, moderate
levels of DA produce optimal cognitive performance, whereas very
high levels of dopamine impair cognition (for review, see Cools and
D’Esposito, 2011).
Thus, nicotine’s addictive and cognition-enhancing properties
appear to be linked at least in part through nicotine-induced
enhancement of DA signaling in the mesolimbic and mesocortical
DA pathways, respectively. Although it should be acknowledged
that the interactions and mutual modulation between DA and
nicotine (as well as endogenous acetylcholine) in both addictive
behavior and cognitive function are certainly more complex than
summarized above.
7. Outstanding questions and future directions
Despite recent progress in nicotine- and tobacco-related neu-
roimaging research, several outstanding questions remain. A major
goal of future research will be to elucidate the relationship and
degree of overlap between the nAChR subtypes and those brain
circuits mediating nicotine’s addiction liability vs. its cognition-
enhancing effects. We envision several lines of investigation, us-
ing complementary and increasingly integrative approaches,
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receptor-level actions to circuit-level effects of acute nicotine
administration by combining PET with pharmacological fMRI in the
same participants. Another gap to be ﬁlled will be to dissociate and
compare the acute and chronic effects of nicotine using prospective
placebo-controlled, double-blind designs with precise nicotine
doses (as opposed to ad libitum smoking). Critical knowledge will
also be gained by elucidating the impact of genetic variation in
cholinergic signaling andmetabolism on all levels of brain function,
from receptor-level to circuit-level, in response to acute and
chronic nicotine, using imaging genetics and imaging pharmaco-
genetics approaches (Hong et al., 2010). Ultimately, well-powered
and well-controlled studies combining neuroimaging, genetics,
and pharmacological manipulations in well-characterized samples
are most likely to produce new breakthroughs and accelerate
translation to clinical treatments.
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